News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx to Present at Two Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. , Aug. 29, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in September:              BioCentury Newsmakers in the Biotech
View HTML
Toggle Summary ChemoCentryx Reports Second Quarter 2019 Financial Results and Recent Highlights
-- Topline data from pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA Vasculitis on track for Q4 2019 -- -- Completed enrollment in LUMINA 1 Phase II trial of CCR2 inhibitor CCX140 in Focal Segmental Glomerulosclerosis (FSGS) -- -- Advancing three additional clinical
View HTML
Toggle Summary ChemoCentryx to Present at the Canaccord Genuity 39th Annual Growth Conference
MOUNTAIN VIEW, Calif. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the Canaccord Genuity 39th Annual Growth Conference on Thursday, August 8, 2019 at 9:30 a.m. ET .
View HTML
Toggle Summary ChemoCentryx to Hold Second Quarter 2019 Financial Results Conference Call on Monday, August 5, 2019
MOUNTAIN VIEW, Calif. , July 31, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's second quarter 2019 financial results will be released after market close on Monday, August 5, 2019 . ChemoCentryx executive management will host a conference call and
View HTML
Toggle Summary ChemoCentryx to Present at Two Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. , June 11, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in June: Raymond James Life Sciences and MedTech Conference Tuesday,
View HTML
Toggle Summary ChemoCentryx Reports First Quarter 2019 Financial Results and Recent Highlights
-- Succession of topline data readouts expected, starting with Pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA Vasculitis in Q4 2019 -- -- Conference call today at 5:00 p.m. Eastern Time -- MOUNTAIN VIEW, Calif. , May 06, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc.
View HTML
Toggle Summary ChemoCentryx to Hold First Quarter 2019 Financial Results Conference Call on Monday, May 6, 2019
MOUNTAIN VIEW, Calif. , April 29, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's first quarter 2019 financial results will be released after market close on Monday, May 6, 2019 . ChemoCentryx executive management will host a conference call and
View HTML
Toggle Summary ChemoCentryx to Present at the H.C. Wainwright Global Life Sciences Conference
MOUNTAIN VIEW, Calif. , April 02, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference on Monday, April 8, 2019 at 9:10 a.m. BST .
View HTML
Toggle Summary ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors
MOUNTAIN VIEW, Calif. , March 28, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), announced today that, effective March 27, 2019 , Rita Jain , M.D., Senior Vice President and Chief Medical Officer of Akebia Therapeutics , has been appointed to the Company's Board of Directors. Dr.
View HTML
Toggle Summary ChemoCentryx Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights
-- Strong Progress Across Company’s Orphan Disease Franchise of Novel Renal and Dermal Therapeutics -- -- Pivotal top-line data expected from ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA-associated  vasculitis, Q4 -- -- Launched AURORA clinical trial of avacopan in
View HTML